-

05:10:02 AM

ALXO Stock News

ALXO - Alx Oncology Holdings Inc

05/09/22 4:01 PM

Nasdaq : ALXO

earningsclinical triallow float

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31,

RHEA-AI

very positive

04/12/22 7:00 AM

Nasdaq : ALXO

managementlow float

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its

RHEA-AI

very positive

03/02/22 7:00 AM

Nasdaq : ALXO

clinical triallow float

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint

RHEA-AI

very positive

02/28/22 7:00 AM

Nasdaq : ALXO

earningsclinical triallow float

ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended

RHEA-AI

neutral

01/27/22 5:51 PM

Nasdaq : ALXO

low float

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”)

RHEA-AI

very positive

01/10/22 6:00 AM

Nasdaq : ALXO

low float

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones

RHEA-AI

positive

01/04/22 7:00 AM

Nasdaq : ALXO

conferenceslow float

ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief

RHEA-AI

neutral

12/14/21 9:00 AM

Nasdaq : DRRX, ALXO

management

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia

DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience. "We are delighted to welcome

RHEA-AI

neutral

12/12/21 9:00 AM

Nasdaq : ALXO

clinical triallow float

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

Objective responses were observed in patients with relapsed/refractory MDS that had progressed after prior hypomethylating

RHEA-AI

neutral

11/11/21 4:05 PM

Nasdaq : ALXO

earningsclinical triallow float

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September

RHEA-AI

positive

1 2 3 4 5 6 Next